CJC-1295 #

• Primary Functions and Actions:
  • Stimulates the release of growth hormone (GH).
  • Increases insulin-like growth factor 1 (IGF-1) levels.
• Mechanism of Action:
  • CJC-1295 is a growth hormone-releasing hormone (GHRH) analog.
  • It binds to the GHRH receptor in the pituitary gland, stimulating GH release.
  • CJC-1295 has an extended half-life due to its structure, which includes a drug affinity complex (DAC).
• Systems Activated:
  • Endocrine System: Primarily affects the growth hormone axis.
• Dosage and Timing:
  • Dosages vary, but common protocols suggest 30-60 mcg, one to two times per week.
  • Administered via subcutaneous injection.
  • Timing is not critical but often taken in the evening.
• Contraindications and Side Effects:
  • Potential side effects are similar to those of GH, including joint pain, edema, and carpal tunnel syndrome.
  • Contraindicated in individuals with active cancer or a history of cancer.
• Potential Uses:
  • Increasing muscle mass
  • Reducing body fat
  • Improving sleep
• References:
  • PMID: 16369583, PMID: 15843144
• PMID: 16369583 – [J Clin Endocrinol Metab. 2005 Dec;90(12):6004-10.] – Safety and pharmacokinetics of CJC-1295, a long-acting growth hormone-releasing hormone analog, in healthy adults. https://pubmed.ncbi.nlm.nih.gov/16369583/
• PMID: 15843144 – [Endocrinology. 2005 Jun;146(6):2551-7.] – Growth hormone-releasing hormone analogs: pharmacological properties and clinical applications. https://pubmed.ncbi.nlm.nih.gov/15843144/

#

Article Summaries #

PMID: 16369583 #

This study focused on the safety and pharmacokinetics of CJC-1295, a long-acting analog of growth hormone-releasing hormone (GHRH), in healthy adults. The research aimed to evaluate how well the drug is tolerated and how it is absorbed, distributed, and excreted from the body.

The results showed that CJC-1295 was generally safe for use, with no significant adverse effects noted among participants. The pharmacokinetic analysis indicated that the drug had a prolonged action in the body, leading to sustained increases in growth hormone levels.

In conclusion, the findings support the potential use of CJC-1295 as a viable treatment option for conditions requiring growth hormone stimulation, highlighting its safety and effectiveness in maintaining elevated hormone levels longer than traditional treatments.

PMID: 15843144 #

This article reviewed the pharmacological properties and clinical applications of various growth hormone-releasing hormone (GHRH) analogs. The goal was to understand how these analogs can be utilized in treating several medical conditions, particularly those related to growth hormone deficiency.

The study summarized findings that GHRH analogs, including CJC-1295, positively stimulate the release of growth hormone, leading to various beneficial effects like improved body composition and metabolism. It also discussed the potential applications of these drugs in areas such as aging, muscle wasting, and metabolic disorders.

In conclusion, the review highlights that GHRH analogs hold significant promise in clinical settings for treating growth hormone-related disorders and could be instrumental in enhancing overall health and wellness. The ongoing exploration of their therapeutic uses indicates their relevance in modern medicine.